Inceptor Bio was established in 2020 with the goal of developing a diversified portfolio of cell therapy platforms across multiple cell types, including chimeric antigen receptor (CAR) T-cells, CAR macrophage cells, and CAR natural killer (NK)/NK-T cells, with novel mechanisms that enhance immune cell performance within the tumor microenvironment.

These products are reliant on the company's AMP+ manufacturing facility, which is a fit-for-purpose, scalable site with viral vector and cell therapy capabilities.

The seed round was led by the Kineticos Disruptor Fund.